Sugi Predict

Sugi Predict / Compounds / SCHEMBL3343241

SCHEMBL3343241

SCHEMBL3343241

CN(C)C(C=O)Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 3/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ EPHX1 P07099 2/20 0.46
▸ SLC6A2 P23975 3/20 0.44
▸ SLC6A4 P31645 2/20 0.44
▸ SLC6A3 Q01959 2/20 0.44
▸ ADRA2B P18089 2/20 0.44
▸ ADRA2C P18825 2/20 0.44
▸ ADRA1A P35348 2/20 0.44
▸ OPRK1 P41145 2/20 0.44
▸ HTR2A P28223 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ HPGD P15428 1/20 0.42
▸ SIGMAR1 Q99720 3/20 0.42
▸ MAOA P21397 2/20 0.42
▸ CYP2A6 P11509 1/20 0.42
▸ ADORA2A P29274 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6606461 1.00 TAAR1 (0.47) TAAR1MEN1KMT2AEPHX1SLC6A2
SCHEMBL27896536 0.81 TAAR1 (0.41) TAAR1ALDH1A1TSHRMAOB
SCHEMBL31080676 0.81 TAAR1 (0.44) TAAR1MEN1KMT2AEPHX1SLC6A2
SCHEMBL19821211 0.80 TAAR1 (0.41) TAAR1MEN1KMT2AEPHX1SLC6A2
SCHEMBL9470007 0.80 ALPI (0.44) TAAR1MEN1KMT2AHPGDALDH1A1
SCHEMBL995542 0.80 SLC6A2 (0.44) TAAR1EPHX1SLC6A2SLC6A4SLC6A3
Hydrochloric Acid SCHEMBL7784340 0.79 TAAR1 (0.43) TAAR1MEN1KMT2AEPHX1SLC6A2
SCHEMBL23019073 0.79 HPGD (0.43) TAAR1MEN1KMT2AEPHX1HPGD
SCHEMBL18376060 0.79 HTR2A (0.51) HTR2ASIGMAR1CYP2A6CYP1A2MAOB
SCHEMBL12522030 0.79 ADRA2B (0.41) TAAR1MEN1KMT2AEPHX1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683622-A1 NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES Pharmapotheca A, Inc. (US) 2026-01-28 — — EP disclosed
WO-2024175957-A1 NON-DISTILLATIVE PROCESS FOR MANUFACTURING HIGH PURITY AMPHETAMINES Pharmapotheca A, Inc. (US) 2024-08-29 — — WO disclosed
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-11-09 — — US disclosed
US-9758487-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-12 — — US disclosed
US-9421192-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-08-23 — — US disclosed
US-20160067223-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2016-03-10 — — US disclosed
US-9227961-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-01-05 — — US disclosed
US-20150011754-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2015-01-08 — — US disclosed
US-8846023-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-09-30 — — US disclosed
EP-2049522-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-05-14 — — EP disclosed
US-20140017195-A1 Hepatitis C Virus Inhibitors BRISTOL MYERS SQUIBB CO (US) 2014-01-16 — — US disclosed
US-8574563-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-05 — — US disclosed
US-20130004457-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2013-01-03 — — US disclosed
US-8329159-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-12-11 — — US disclosed
US-8303944-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-06 — — US disclosed
US-20100172924-A1 CIRCOVIRUS SEQUENCES ASSOCIATED WITH PIGLET WEIGHT LOSS DISEASE (PWD) WYETH (US) 2010-07-08 — — US disclosed
US-20100158862-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 — — US disclosed
CN-1525249-B Polymerizable composition and lithographic printing plate precursor FUJI PHOTO FILM CO LTD 2010-05-05 — — CN disclosed
CN-1525249-A Polymerizable composition and lithographic printing plate precursor ��ʿ��Ƭ��ʽ���� 2004-09-01 — — CN disclosed
CN-1354750-A Amine derivatives compounds SANKYO CO (JP) 2002-06-19 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160067223-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS TAAR1 4513/4885MEN1 4867/4885KMT2A 4516/4885
US-20170320833-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS TAAR1 4513/4885MEN1 4867/4885KMT2A 4516/4885
US-20130004457-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS TAAR1 4513/4885MEN1 4867/4885KMT2A 4516/4885
US-20150011754-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS TAAR1 4513/4885MEN1 4867/4885KMT2A 4516/4885
US-20140017195-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS TAAR1 4513/4885MEN1 4867/4885KMT2A 4516/4885
US-20100158862-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS TAAR1 4513/4885MEN1 4867/4885KMT2A 4516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.